StreetInsider.com News Articles

Form 8-K NEONC TECHNOLOGIES HOLDI For: Jun 16

Thu, 18 Jun 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260618/26667064.html

Form 8-K NEONC TECHNOLOGIES HOLDI For: Jun 16

Thu, 18 Jun 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260618/26667064.html

Biotech's New Frontier: Companies Breaking Through Medicine's Toughest Barriers

Wed, 17 Jun 2026 10:37:33 -0400

These companies are Pushing Boundaries, including the Blood Brain Barrier

DENVER, June 17, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – The biotechnology space is delivering a steady stream of potentially market-moving developments this week as companies across oncology, neuroscience, gene therapy, medical devices, and synthetic biology delivered significant regulatory, clinical, and commercial updates.

NeOnc Technologies Holdings Advances Toward Critical Neuro-Oncology Milestones

NeOnc (NASDAQ: NTHI) is becoming one of the more closely watched emerging neuro-oncology companies after securing a significant international regulatory milestone. The Department of Health – Abu Dhabi granted Investigational New

Biotech's New Frontier: Companies Breaking Through Medicine's Toughest Barriers

Wed, 17 Jun 2026 10:37:33 -0400

These companies are Pushing Boundaries, including the Blood Brain Barrier

NeOnc Technologies Holdings Advances Toward Critical Neuro-Oncology Milestones

Biotech's New Frontier: Companies Breaking Through Medicine's Toughest Barriers

Wed, 17 Jun 2026 10:37:33 -0400

These companies are Pushing Boundaries, including the Blood Brain Barrier

NeOnc Technologies Holdings Advances Toward Critical Neuro-Oncology Milestones

Biotech's New Frontier: Companies Breaking Through Medicine's Toughest Barriers

Wed, 17 Jun 2026 10:37:33 -0400

These companies are Pushing Boundaries, including the Blood Brain Barrier

NeOnc Technologies Holdings Advances Toward Critical Neuro-Oncology Milestones

Biotech's New Frontier: Companies Breaking Through Medicine's Toughest Barriers

Wed, 17 Jun 2026 10:37:33 -0400

These companies are Pushing Boundaries, including the Blood Brain Barrier

NeOnc Technologies Holdings Advances Toward Critical Neuro-Oncology Milestones

Biotech's New Frontier: Companies Breaking Through Medicine's Toughest Barriers

Wed, 17 Jun 2026 10:37:33 -0400

These companies are Pushing Boundaries, including the Blood Brain Barrier

NeOnc Technologies Holdings Advances Toward Critical Neuro-Oncology Milestones

Biotech's New Frontier: Companies Breaking Through Medicine's Toughest Barriers

Wed, 17 Jun 2026 10:37:33 -0400

These companies are Pushing Boundaries, including the Blood Brain Barrier

NeOnc Technologies Holdings Advances Toward Critical Neuro-Oncology Milestones

Biotech's New Frontier: Companies Breaking Through Medicine's Toughest Barriers

Wed, 17 Jun 2026 10:37:33 -0400

These companies are Pushing Boundaries, including the Blood Brain Barrier

NeOnc Technologies Holdings Advances Toward Critical Neuro-Oncology Milestones

NeOnc's Global Expansion Accelerates After Abu Dhabi IND Approval for NEO212

Wed, 17 Jun 2026 09:18:11 -0400

InvestorsTape.com Closely Watching NTHI Ahead of Multiple Clinical, Regulatory, and Data Catalysts

DALLAS, June 17, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings (NASDAQ: NTHI) is rapidly emerging as a development-stage neuro-oncology innovator, as it advances a growing pipeline of therapies designed to address some of the most difficult cancers to treat.

Its critical data efforts received a significant boost after the company announced that the Department of Health – Abu Dhabi granted Investigational New Drug (IND) authorization for NEO212, NeOnc's oral perillyl alcohol-temozolomide conjugate being developed for aggressive brain tumors, including glioblastoma.

The authorization marks the first

NeOnc's Global Expansion Accelerates After Abu Dhabi IND Approval for NEO212

Wed, 17 Jun 2026 09:18:11 -0400

InvestorsTape.com Closely Watching NTHI Ahead of Multiple Clinical, Regulatory, and Data Catalysts

The authorization marks the first

NeOnc's Global Expansion Accelerates After Abu Dhabi IND Approval for NEO212